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Abstract: Non-alcoholic fatty liver disease (NAFLD) is gaining in importance and is linked to obesity.
Especially, the development of fibrosis and portal hypertension in NAFLD patients requires treatment.
Transgenic TGR(mREN2)27 rats overexpressing mouse renin spontaneously develop NAFLD with
portal hypertension but without obesity. This study investigated the additional role of obesity in this
model on the development of portal hypertension and fibrosis. Obesity was induced in twelve-week
old TGR(mREN2)27 rats after receiving Western diet (WD) for two or four weeks. Liver fibrosis
was assessed using standard techniques. Hepatic expression of transforming growth factor-β1
(TGF-β1), collagen type Iα1, α-smooth muscle actin, and the macrophage markers Emr1, as well as
the chemoattractant Ccl2, interleukin-1β (IL1β) and tumor necrosis factor-α (TNFα) were analyzed.
Assessment of portal and systemic hemodynamics was performed using the colored microsphere
technique. As expected, WD induced obesity and liver fibrosis as confirmed by Sirius Red and Oil Red
O staining. The expression of the monocyte-macrophage markers, Emr1, Ccl2, IL1β and TNFα were
increased during feeding of WD, indicating infiltration of macrophages into the liver, even though this
increase was statistically not significant for the EGF module-containing mucin-like receptor (Emr1)
mRNA expression levels. Of note, portal pressure increased with the duration of WD compared
to animals that received a normal chow. Besides obesity, WD feeding increased systemic vascular
resistance reflecting systemic endothelial and splanchnic vascular dysfunction. We conclude that
transgenic TGR(mREN2)27 rats are a suitable model to investigate NAFLD development with liver
fibrosis and portal hypertension. Tendency towards elevated expression of Emr1 is associated with
macrophage activity point to a significant role of macrophages in NAFLD pathogenesis, probably
due to a shift of the renin–angiotensin system towards a higher activation of the classical pathway.
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The hepatic injury induced by WD in TGR(mREN2)27 rats is suitable to evaluate different stages of
fibrosis and portal hypertension in NAFLD with obesity.
Keywords: ADGRE1; EMR1; F4/80; immunity; liver fibrosis; macrophage; NAFLD; portal hypertension;
TGR(mREN2)27; Western diet
1. Introduction
Non-alcoholic fatty liver disease (NAFLD) has become one of the leading causes of cirrhosis in
some countries due to the demographic change [1]. Especially fibrosis and development of portal
hypertension have been shown to determine the necessity for treatment of NAFLD patients [2,3].
Development of portal hypertension is associated with morbidity and mortality in these patients [4,5].
Increased physical activity and reduction of weight are the current therapy strategies for NAFLD
patients. If patients are able to lose five to ten percent of their weight, there is a chance to reduce hepatic
fibrosis and inflammation, which is seen by an improvement in liver enzymes as well as reduced
hepatic steatosis. However, many patients struggle with weight reduction and lifestyle change due
to unhealthy dietary patterns and sedentary lifestyle [6], which emphasizes the need for adequate
medical therapy, stopping the progress of fibrosis and portal hypertension in NAFLD.
The pathogenesis of NAFLD is complex and there are a number of drugs addressing NAFLD
development, but not many that address fibrosis and portal hypertension [7]. One reason is the lack of
suitable animal models, which are especially important for preclinical drug testing. In this study, we
tried to create such a model using TGR(mREN2)27 rats after induction of obesity to investigate fibrosis
and portal hypertension. The model of transgenic TGR(mREN2)27 rats, in which the mouse Ren-2
renin gene is inserted into the genome of the rat, was described in previous studies [8–11].
Activation of hepatic stellate cells (HSCs) leads to increased synthesis and deposition of collagen
and other components of the extracellular matrix (ECM). Portal pressure is increased by the resulting
stiffening of the liver and increased contractility of activated HSC [12]. In all these processes,
the renin–angiotensin system (RAS) plays an important role, as renin is upregulated in human NASH
patients. Higher levels of renin lead to an increased synthesis of angiotensin I and consequently
angiotensin II, which is the agonist of the pro-fibrotic and pro-contractile AT1 receptor. This receptor
facilitates fibrosis and portal hypertension through Janus kinase 2 (JAK2) in HSCs [13,14]. The role of
angiotensin II induced AT1 receptor stimulation has already been demonstrated by Bataller et al. and
supports our hypothesis [15,16].
In all these processes, macrophages originating from monocytic precursors have multiple functions.
In particular, they are key regulators of liver repair, regeneration, and development of fibrosis.
Particularly, the monocyte chemoattractant protein-1 (MCP-1), expressed by the gene Ccl2, is a
key factor driving liver macrophage infiltration and steatosis [17]. Therefore, this chemokine has
recently attracted much attention for the development of therapeutic strategies targeting NAFLD
development [18–20]. In this regard, the EMR1, representing the mouse gene encoding the F4/80
antigen, has been proposed as a robust marker of liver-resident macrophages deriving from embryonic
progenitors and as renewed independently of blood monocytes [21,22]. Since the pathophysiology
of NAFLD is multifactorial and not yet completely understood, models for analyzing the impact
of liver-resident macrophages (Kupffer cells) and infiltrating macrophages are urgently needed for
analyzing the complex mechanisms of respective disease.
The overexpression of the mouse renin in TGR(mREN2)27 rats leads to chronic hypertension and
spontaneous development of NAFLD with fibrosis and portal hypertension, but without obesity [10,11].
However, in humans obesity is strongly associated with hepatic steatosis [6]. Moreover, it was
shown that obesity aggravates portal hypertension [23,24]. As obesity is strongly linked to NAFLD,
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the influence of obesity for the development of hepatic fibrosis and portal hypertension in NAFLD is
an interesting research topic.
In this study, we analyzed the expression of Emr1 and Ccl2 during the onset of NAFLD. We aimed
an aggravation of fibrosis and portal hypertension after induction of obesity receiving two and four
weeks of Western diet (WD) in TGR(mREN2)27 rats. Our results indicate that this transgenic model is
a suitable model to investigate aspects of NAFLD development when fed with the WD diet.
2. Results
2.1. Western Diet Induced Obesity in TGR(mREN2)27 Rats
Two and four weeks of WD induced obesity in TGR(mREN2)27 rats (Figure 1A). In detail, rats
receiving normal chow had a mean weight of 279 ± 13 g versus rats receiving WD for two weeks with
a mean weight of 315 ± 7 g (p < 0.005) and rats receiving WD for four weeks with a mean weight of
341 ± 6 g (p < 0.005) (Table 1).Int. J. Mol. Sci. 2 20, 21, x FOR PEER REVIEW 4 of 15 
 
 
Figure 1. Fibrosis in transgenic TGR(mREN2)27 rats after high fat Western diet. (A) Ten-week-old 
rats received either normal chow for 4 weeks, or normal chow for 2 weeks followed by Western diet 
for 2 weeks or Western diet for 4 weeks before hemodynamic measurements and harvesting of the 
organs. (B) Hepatic Sirius Red staining show more collagen deposition in TGR(mREN2)27 rats 
receiving WD compared to normal chow. (C) The densitometric analysis of (A) shows an increase of 
collagen positive areas after 2 and 4 weeks of WD feeding. (D). Collagen 1α1 (Col1α1) mRNA 
expression quantified by RT-qPCR is increased in livers of TGR(mREN2)27 rats after 2 weeks of WD. 
After 4 weeks, a decrease in Col1α1 levels are noticed, still being higher compared to rats receiving 
normal chow. (E) Livers of TGR(mREN2)27 rats receiving 2 or 4 weeks of WD express significantly 
more tumor growth factor-β (TGF-β) than TGR(mREN2)27 rats fed with normal chow. */*** p < 
0.05/0.01 vs. normal chow, ## p < 0.01 vs. 2 weeks high fat Western diet.  
Additionally, α-SMA immunohistochemistry revealed an increase with the duration of WD, 
confirmed by α-SMA quantification (Figure 2) as a marker of HSC activation. 
 
Figure 2. α-smooth muscle actin (α-SMA) expression in transgenic TGR(mREN2)27 rats after high fat 
Western diet. (A) Hepatic α-SMA staining increased after 2 and 4 weeks of WD (left panel). (B) This 
Figure 1. Fibrosis in transgenic TGR(mREN2)27 rats after high fat Western diet. (A) Ten-week-old rats
received either normal chow for 4 weeks, or normal chow for 2 weeks followed by Western diet for 2
weeks or Western diet for 4 weeks before hemodynamic measurements and harvesting of the organs.
(B) Hepatic Sirius Red staining show more collagen deposition in TGR(mREN2)27 rats receiving WD
compared to normal chow. (C) The densitometric analysis of (A) shows an increase of collag n p sitive
areas after 2 and 4 w eks of WD feeding. (D). C llagen 1α1 (Col1α1) mRNA expression quantified by
RT-qPCR i increased in livers of TGR(mREN2)27 rats after 2 weeks of WD. After 4 , a decrease
in Col1α1 levels are noticed, still being higher compared to rats receiving normal chow. (E) Livers of
TGR(mREN2)27 rats receiving 2 or 4 weeks of WD express significantly more tumor growth factor-β
(TGF-β) than TGR(mREN2)27 rats fed with normal chow. */*** p < 0.05/0.01 vs. normal chow, ## p < 0.01
vs. 2 weeks high fat Western diet.
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Table 1. Body weight, liver weight and spleen weight of rats receiving normal chow, 2 weeks and 4
weeks high fat Western diet.
Rat treatment Body Weight (g) Liver Weight (g) Spleen Weight (g)
Normal chow 279.3 ± 13.2 11.4 ± 2.3 0.6 ± 0.7
High fat Western diet (2 wks) 315.4 ± 6.7 *** 12.1 ± 1.4 0.6 ± 0.2
High fat Western diet (4 wks) 341.0 ± 6.4 ***# 13.7 ± 1.7 * 0.6 ± 0.1
*/*** p < 0.05/0.001 vs. normal chow, # p < 0.05 vs. 2 weeks high fat Western diet.
2.2. Western Diet Aggravated Liver Fibrosis in TGR(mREN2)27 Rats
Next, we analyzed, whether WD influenced liver fibrosis. The extent of fibrosis was assessed
histologically in these animals. WD for two weeks increased the degree of liver fibrosis in
TGR(mREN2)27 rats using Sirius Red staining (Figure 1B). This effect was even further aggravated after
four weeks of WD, which was also observed in the quantification of hepatic Sirius red staining showing
a significant difference compared to rats with normal chow (Figure 1C). This finding was confirmed by
higher levels of collagen type I α1 (ColIα1) mRNA, however there was no further increase seen after
four weeks of WD (Figure 1D). These results were also supported by the hepatic mRNA expression of
fibrosis parameters like transforming growth factor-β (TGF-β) (Figure 1E).
Additionally, α-SMA immunohistochemistry revealed an increase with the duration of WD,
confirmed by α-SMA quantification (Figure 2) as a marker of HSC activation.
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Figure 2. α-smooth muscle actin (α-SMA) expression in transgenic TGR(mREN2)27 rats after high fat
Western diet. (A) Hepatic α-SMA staining increased after 2 and 4 weeks of WD (left panel). (B) This
effect is also seen in the quantification of α-SMA staining by densitometry. ** p < 0.01 vs. normal chow.
2.3. Western Diet Induced Activation of Macrophages in TGR(mREN2)27 Rats
F4/80 immunostaining suggest an increase of macrophages in TGR(mREN2)27 rats after WD
feeding (Figure 3A). Interestingly, we could show a tendency towards M1 macrophage increase as
shown by Emr1 expression (Figure 3B). Moreover, we observed an increase in Ccl2 (Figure 3C),
Il1β (Figure 3D), and TNFα (Figure 3E) mRNA levels in TGR(mREN2)27 rats after WD diet compared
to rats fed a normal chow.
2.4. Western Diet Induced NAFLD in TGR(mREN2)27 Rats
As a proof for NAFLD development in TGR(mREN2)27 rats we demonstrated an increase in
hepatic fat content and hepatic mRNA and protein expression of two key genes involved in lipogenesis;
sterol regulatory element binding protein-1c (SREBP-1c) and fatty acid synthase (FAS) (Figure 4).
The increase of SREBP1C levels was statistically significant after four weeks of WD while the increase
of FAS was not significant. Induction of NAFLD was also seen in the quantifications of Oil Red O
stainings and a significant increase in hepatic triglyceride content after two and four weeks of WD.
Int. J. Mol. Sci. 2020, 21, 3308 5 of 14
Int. J. Mol. Sci. 2020, 21, x FOR PEER REVIEW 5 of 15 
 
effect is also seen in the quantification of α-SMA staining by densitometry. ** p < 0.01 vs. normal 
chow. 
2.3. Western Diet Induced Activation of Macrophages in TGR(mREN2)27 Rats 
F4/80 immunostaining suggest an increase of macrophages in TGR(mREN2)27 rats after WD 
feeding (Figure 3A). Interestingly, we could show a tendency towards M1 macrophage increase as 
shown by Emr1 expression (Figure 3B). Moreover, we observed an increase in Ccl2 (Figure 3C), Il1β 
(Figure 3D), and TNFα (Figure 3E) mRNA levels in TGR(mREN2)27 rats after WD diet compared to 
rats fed a normal chow. 
 
Figure 3. Hepatic assessment of macrophages and subgroup M1. (A) Hepatic frozen sections of 
TGR(mREN2)27 rats fed with normal chow, with 2 or 4 weeks of high fat Western diet were stained 
with the macrophage marker F4/80. Black arrow highlights positive cells. (B) Increased epidermal 
growth factor module-containing mucin-like receptor (Emr1) expression suggests increased numbers 
of macrophages after 4 weeks of WD feeding. (C) Increased expression of in CC-chemokine ligand 2 
(Ccl2) was noticed after 4 weeks of WD feeding. (D,E) mRNA level of Il1β and TNFα confirmed the 
inflammatory effect after 2 and 4 weeks of WD feeding. */** p < 0.05/0.01 vs. normal chow. 
2.4. Western Diet Induced NAFLD in TGR(mREN2)27 Rats 
As a proof for NAFLD development in TGR(mREN2)27 rats we demonstrated an increase in 
hepatic fat content and hepatic mRNA and protein expression of two key genes involved in 
lipogenesis; sterol regulatory element binding protein-1c (SREBP-1c) and fatty acid synthase (FAS) 
(Figure 4). The increase of SREBP1C levels was statistically significant after four weeks of WD while 
the increase of FAS was not significant. Induction of NAFLD was also seen in the quantifications of 
Oil Red O stainings and a significant increase in hepatic triglyceride content after two and four 
weeks of WD. 
Figure 3. Hepatic assessment of macrophages and subgroup M1. (A) Hepatic frozen sections of
TGR(mREN2)27 rats fed with normal chow, with 2 or 4 weeks of high fat Western diet were stained
with the macrophage marker F4/80. Black arrow highlights positive cells. (B) Increased epidermal
growth factor module-containing mucin-like receptor (Emr1) expression suggests increased numbers
of macrophages after 4 weeks of WD feeding. (C) Increased expression of in CC-chemokine ligand 2
(Ccl2) was noticed after 4 weeks of WD feeding. (D,E) mRNA level of Il1β and TNFα confirmed the
inflammatory effect after 2 and 4 weeks of D feeding. */** p < 0.05/0.01 vs. normal chow.
2.5. Western Diet Aggravated Portal Hypertension in TGR(mREN2)27 Rats
Since fibrosis was aggravated, we analyzed the magnitude of portal hypertension in
TGR(mREN2)27 ra s after WD. Interestingly, the additional WD in TGR(mREN2)27 rats aggravated
portal hyperten ion known to have already a pri ri portal hypertension (Figure 5A), with a further
increase after four weeks f WD. Hepatic-portal vascular resistance (HPVR) as higher in WD rats
(Table 2, Figure 5B). In trend, mean arterial pressure was decreased in two and four weeks WD rats
(Figure 5C) but did not reach significance. Cardiac output was decreased in TGR(mREN2)27 rats
receiving two or four weeks of WD compared to the control group receiving normal chow (Figure 4D).
The renal arterial flow in TGR(mREN2)27 rats was investigated using the colored microsphere technique.
WD did not change renal arterial flow significantly (Figure 5E).
Table 2. Hemodynamics in transgenic TGR(mREN2)27 rats with normal chow vs. 2 and 4 weeks of
Western diet.
TGR(mREN2)27
Groups
Portal Pressure
(mmHg)
Hepatic-Vascular
Resistance
(mmHg*min*g
Liver/mL)
Splanchnic-Vascular
Resistance
(mmHg*min*100g/mL)
Mean Arterial
Pressure (mmHg)
Systemic-Vascular
Resistance
(mmHg*min*100g/mL)
normal chow 11.24 ± 0.53 6.31 ± 0.83 49.92 ± 11.12 129.73 ± 6.68 4.68 ± 0.89
2 weeks
Western diet 14.00 ± 1.29 * 15.91 ± 5.11 * 23.05 ± 4.42 * 117.40 ± 2.91 5.54 ± 0.65
4 weeks
Western diet 21.50 ± 2.18 **## 19.36 ± 3.94 ** 23.48 ± 4.70 * 127.80 ± 4.49 5.57 ± 0.75
*/** p < 0.05/p < 0.01 vs. TGR(mRen2)27 with normal chow; ## p < 0.01 vs. TGR(mRen2)27 after 2 weeks of
Western diet.
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Figure 4. Steatosis assessment in TGR(mREN2)27 rats. Effect of 2 weeks and 4 weeks of high fat diet
in liver steatosis in TGR(m EN2)27 rats. (A) Represe t ti e il Red O stai ing and polarized light
imaging (magnification ×100) of livers from TGR(m EN2)27 rats fed with normal chow, 2 and 4 weeks
of high fat diet. (B) Levels of hepatic triglyceride content in TGR(mREN2)27 rats fed with normal chow
and with 2 or 4 weeks of high fat diet. (C) Western blots of steatosis marker proteins (sterol regulatory
element-binding protein 1c (Srebp-1c), fatty acid synthase (FAS)) and their quantification (D,E). The scale
bar is 100 µm. Results are represented as mean ± SEM. For comparisons a two-tailed student´s unpaired
t-test was performed; controls, n = 5 normal chow TGR(mREN2)27; n = 5 TGR(mREN2)27 with 2 weeks
of high fat diet; n = 5 TGR(mREN2)27 with 4 weeks of high fat diet. All analyses were carried out using
GraphPad Prism. * p < 0.05 vs. TGR( REN2)27 rats fed with normal chow.
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Figure 5. Hepatic and systemic effects of Western diet in TGR(mREN2)27 rats. (A) Portal pressure
is increased after two and four weeks of D. (B) Hepatic portal-vascular resistance increases after
WD. (C) Mean arterial pressure sho relevant alteration after WD feeding. (D) Card ac output
is reduced in rats receiving WD. (E) The renal arterial flow in TGR(mREN2)27 rats was investigated
using the colored microsphere technique. Columns illustrate the renal arterial flow in mL/min/g kidney
of rats. */** p < 0.05/0.01 vs. normal chow.
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2.6. Western Diet and Role of RAS in TGR(mREN2)27 Rats
We analyzed the role of RAS in TGR(mREN2)27 rats after WD. We could show an increase in
ACE1 expression and decrease in ACE2 levels (Figure 6A). Angiotensin-1-receptor and Mas-receptor
were increased significantly after four weeks of WD (Figure 6B,C).Int. J. Mol. Sci. 2020, 21, x FOR PEER REVIEW 8 of 15 
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liver disease. RAS upregulation activates a signaling cascade via angiotensin I and angiotensin II, 
which is the agonist of the pro-fibrotic and pro-contractile AT1 receptor. Stimulation of the AT1 
receptor in HSC induces fibrosis and portal hypertension through Janus kinase 2 (JAK2) [13,14]. As a 
Figure 6. Western diet and RAS in TGR(mREN2)27 rats. Effect of high fat Western diet in RAS-system
in TGR(mREN2)27 rats. (A) Increase in ACE and decrease in ACE2 levels. (B,C) Angiotensin-1-receptor
and Mas-receptor were upregulated after two and four weeks of WD. */** p < 0.05/0.01 vs. normal chow.
3. Discussion
This study describes a modification of the liver pathology in the TGR(mREN2)27 rat model with
induction of obesity, with relevant changes in macrophage infiltration, fibrosis and portal hypertension.
We could show that WD induces obesity in this rat model and aggravates portal hypertension und
fibrosis as well as an upregulation of fibrosis parameters, reac ing significance especially for TGF-β
mRNA. Moreover, expression levels of Emr1 and Ccl2 that, both activ te macrophage recruitment, are
increased during WD feeding.
NAFLD is an emerging etiology of liver disease. Portal hypertension is a frequent complication in
NAFLD, especially in advanced disease stages [25]. It has been described elsewhere that TGR(mREN2)27
rats spontaneously develop pronounced steatosis and inflammation after twelve weeks of life [10].
Additionally, we could demonstrate that TGR(mREN2)27 rats also develop mild fibrosis and significant
portal hypertension in the absence of any special diet [11] and might be used as a model for NAFLD
research. The additional effect and role of obesity was not investigated in TGR(mREN2)27 rats so far,
even though obesity is strongly linked t NAFLD. In NAFLD, arterial hypertensio and obesity are both
part of the metabolic syndrome. In ur model we induced obesity by WD in TGR(mREN2)27 rats, which
spontaneously show arterial hypertension. This is probably a different s quence of mechanism le ding
to NASH, having arterial hypertension as a first hit. It was previously shown that in NAFLD arterial
hypertension was associated with progression of fibrosis [26,27]. Unfortunately, although arterial
hypertension is a risk factor for progression of fibrosis, our animal models demonstrates that arterial
hypertension as the first hit seems not to be a strong inductor of fibrosis but of portal hypertension.
Nevertheless the spontaneous development of NALFD in TGR(mREN2)27 rats overexpressing
mouse renin underlines the pathogenic role of the renin-angiotensin system (RAS) in non-alcoholic
liver dis ase. RAS upregulation activates a signali c scade via angiotensin I and angiotensin II,
which is t e agonist of the pro-fibrotic and pro-contra receptor. Stimulati n of the AT1
receptor in HSC induces fibrosis and portal hypertension t Janus kinase 2 (JAK2) [ 3,14]. As a
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consequence, inhibition of renin leads to improved liver fibrosis and reduction in portal hypertension.
Overexpression of angiotensin II induces NAFLD in TGR(mREN2)27 rats [10].
There are studies investigating the effects of obesity on portal hypertension and fibrosis in
patients with cirrhosis, showing that obesity aggravates portal hypertension due to an upregulation
of pro-inflammatory, pro-fibrogenic and pro-angiogenic processes [23,24]. These findings comply
with the results of our study, showing that WD for two or four weeks aggravated fibrosis and portal
hypertension in transgenic TGR(mREN2)27 rats.
We could show that TGR(mREN2)27 rats fed with WD show activation of macrophages, mainly M1.
It is known that NAFLD as hepatic manifestation of metabolic disease is driven by chronic inflammatory
processes in which macrophages play an important role. The polarization status of macrophages is
influenced by metabolic stimuli such as fatty acids. There is increasing evidence from animal and
clinical studies that macrophage targeting may be an effective therapeutic strategy for NAFLD [28].
Two macrophage populations are involved in chronic liver injury, the liver-resident Kupffer cells and
the inflammatory monocyte-derived macrophages [29]. We could demonstrate a significant increase in
gene expression of TGF-β and a relevant increase in Emr1 and Ccl2 mRNA levels, even though for
Emr1 the increase was statistically not significant. TGF-ß, Emr1 and Ccl2 play an important role in
the recruitment and activity of macrophages, which are key drivers in the pathogenesis of fibrosis.
Emr1, originally named F4/80, is a mouse macrophage-restricted protein expressed in liver-resident
Kupffer cells and in many macrophage populations [30,31]. Therefore, this surface protein is still the
best marker to identify tissue macrophages [32]. An upregulation of Ccl2 expression preceded the
increase of macrophages. MCP-1 is the main chemotactic factor necessary to recruit monocytes into
foci of active inflammation and directly mediates a pro-fibrotic effect on fibroblasts by affecting TGF-β
signaling. This in turn, stimulates synthesis and deposition of collagen [33]. In line, mice lacking
the receptor for MCP-1 showed reduced infiltration and inflammatory macrophages in experimental
fibrosis [34]. Therefore, the TGR(mREN2)27 rat model when fed with WD is a suitable NAFLD model
that mimics key aspects of inflammation, fibrosis, portal hypertension and development of obesity.
The Baveno VI guideline acknowledge that co-factors of liver injury may maintain portal
hypertension [35]. Surveillance for complications of portal hypertension such as variceal progress is
stratified by co-factors such as obesity and alcohol abuse. In our earlier studies, we investigated the
effect of an additional cholestatic or toxic liver injury in the model of TGR(mREN2)27 rats, not showing a
relevant aggravation of portal hypertension and fibrosis, probably due to decreased expression of mouse
renin in hepatocytes [11]. In this study, we could demonstrate that obesity increases portal hypertension
in TGR(mREN2)27 rats, underlining the importance of this co-factor in surveillance of complications of
portal hypertension. Spontaneous portal hypertension in TGR(mREN2)27 rats is mediated by increased
portal pressure and hepatic vascular resistance [11]. When WD is admitted and obesity is induced the
features of portal hypertension seem to be different. The detailed hemodynamic assessment of our study
demonstrates that the hemodynamic effects were probably also mediated via extrahepatic components
of the diet, possibly on the gut permeability mediating splanchnic hyperperfusion. This is in line with
previous and recent results, demonstrating that diet and microbiome might play an important role in
the development of fatty liver, mainly due to systemic or intestinal inflammation [36–38]. We failed
to show an upregulated inflammation in these animals upon WD, and therefore assume that the
additional hepatic effects of WD are independent of the liver phenotype.
Mouse and rat renin show a homology of 88% [39]. Mullins et al. showed that the introduction of
the mouse Ren-2 renin gene into the genome of the rat caused arterial hypertension, demonstrating
that the mouse renin gen is fully active in rats [8]. Our work demonstrates a shift towards higher AT1
receptor stimulation due to increased ACE expression and decreased ACE2 expression with increased
AT1 and MAS receptor mRNA expression levels. This may indicate that the underlying mechanism is
a shift towards the classical renin–angiotensin system pathway.
Our study has several limitations. Firstly, we used an artificial transgenic rat model with very little
spontaneous steatosis. However, we know that renin is upregulated in human NASH patients similar
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to our TGR(mREN2)27 rat model. Secondly, we did not have a wild-type control group, however the
research question was to analyze the additional effect of WD to RAS overexpression. Rats were only
fed for maximum of four weeks with WD. A longer feeding period would be interesting to further
analyze hypertension and fibrosis. However, prolongation of the feeding period with WD would
lead to more severe illness due to uncontrolled arterial hypertension. Furthermore, we have only
performed mRNA expression studies for Emr1, Ccl2, IL1β and TNFα. However, a previous study in
kidney has shown that the TGR(mREN2)27 rats, developing angiotensin II-dependent hypertension,
exhibited a more marked infiltration of macrophages than normotensive rats combined with elevated
MCP-1/CCL2 expression during experimental inflammation [39]. Therefore, another limitation of this
study is the lack of protein data for F4/80 and MCP-1 as well as CXCR3 levels.
In summary, our study shows that WD induces obesity in TGR(mREN2)27 rats and aggravates
NAFLD, portal hypertension and fibrosis. In line, we observed an upregulation of profibrotic markers
especially TGF-β and an activation of macrophages seen by increased Ccl2 and Emr1 mRNA expression.
Probably the surplus on angiotensin II generation by increased ACE and AT1 receptor expression is a
trigger for increased fibrosis and portal hypertension in our model. This may be also confirmed by
previous studies, which show that AT1 receptor stimulation induces fibrosis and activation of hepatic
stellate cells [15]. This may explain our findings. Therefore, this model is proposed as a suitable tool to
analyze the pathogenic events of fibrosis and portal hypertension occurring during the pathogenesis
of NAFLD.
4. Materials and Methods
4.1. Animals and Models of Liver Disease
For our experiments, we used five TGR(mREN2)27 rats per group (normal chow, WD for two
weeks, WD for four weeks), giving a total number of 15 animals. It is known that in TGR(mREN2)27
rats NAFLD is established after twelve weeks of life [10]. Ten week old TGR(mREN2)27 rats received
either normal chow for 4 weeks, or normal chow for 2 weeks followed by Western diet for 2 weeks or
Western diet for 4 weeks before hemodynamic measurements and harvesting of the organs (Figure 1A).
Experimental procedures were approved by the Animal Ethics Committee of North Rhine-Westphalia
(approval code: LANUV 84-02.04.2014.A137; approval date: 28.05.2014). Rats were housed in
individually ventilated cages with a12-hour light/12-hour dark cycle and temperature of 22 to 24 ◦C).
Animals were fed standard rat chow ad libitum (Ssniff, Soest, Germany) with free access to water.
For induction of obesity, TGR(mREN2)27 rats were fed for two or four weeks with WD ad libitum
(20.85% fat, 19.5% casein, 1.25% cholesterol; Ssniff) as previously described [40] following standardized
protocols [10,41]. The rationale to use WD is based on our previous work in which we induced NASH
in another model [40].
4.2. Hemodynamic Studies
For the in-vivo hemodynamic studies, TGR(mREN2)27 rats were used after two and four weeks
of WD as described previously [14,42] and compared to TGR(mREN2)27 rats receiving normal
chow. To assess the effect of WD, mean arterial pressure and portal pressure were measured
invasively. The colored microsphere technique was performed to investigate hemodynamics as
described previously [14,42]. Briefly, 300,000 systemic (red/white) microspheres (15 µm diameter,
Triton-Technologies, San Diego, CA, USA) were injected in the left ventricle and 150,000 microspheres
(yellow/blue) were injected in the portal vein through the ileocecal vein to estimate the mesenteric
portal-systemic shunt volume.
4.3. Tissue Collection
After the final experiment, animals were anesthetized and laparotomy was performed for tissue
collection. The livers were cut into fragments and stored at −80 ◦C until further use as described
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previously [43,44]. Segments of each liver were fixed in formaldehyde (4%) for paraffin embedding,
as described previously [13,44].
4.4. Sirius Red Staining and α-Smooth Muscle Actin Immunohistochemistry
Hepatic fibrosis was assessed in paraffin embedded liver sections (2–3 µm) stained with 0.1%
Sirius Red in saturated picric acid (Chroma, Münster, Germany). Immunohistochemistry against
α-smooth muscle actin (α-SMA) was performed in snap frozen liver samples. Cryosections (5–10
µm) of liver samples were fixed and incubated with mouse anti-α-SMA antibody (Sigma Aldrich,
Munich, Germany) and a biotinylated donkey anti rat secondary antibody (Abcam, Cambridge, UK).
Stained sections were digitalized using Pannoramic MIDI (3DHISTECH, Budapest, Hungary) and
positive staining was quantified using Histoquant (3DHISTECH, Budapest, Hungary), as previously
described [13,44].
4.5. Oil Red O Staining
Hepatic steatosis was assessed using Oil Red O stainings and performed as described
previously [40,45]. Stainings were captured with a Nikon Digital Sight DS-Vi1 (Chiyoda, Tokyo, Japan).
A minimum of 10 high-power fields was captured for analysis.
4.6. F4/80 Staining
Macrophage staining of livers were assessed in slides of frozen sections (5–10 µm). Slides were
fixed in ice cold ethanol for 15–20 min. Slides were air-dried for 10 min and washed in PBS 2 times for
2 min. Thereafter, slides were quenched in 0.3% H2O2 for 10 min. PBS washing was repeated for 2 min
and air dried. Then, 1–2 drops of Avidin solution (Abcam, Cambridge, UK) were added on each slide
and incubated for 10 min. The washing procedure was repeated for 2 min. Next, 1–2 drops of Biotin
blocking solution (Abcam) were added to each slide and incubated for 10 min at room temperature.
After 2 times of washing in PBS, slides were incubated with 10% FCS for 30 min. Afterwards the
diluted anti-F4/80 antibody (Merck, Taufkirchen, Germany) was given to slides and incubated for 2
hours. The slides were washed twice in PBS for 4 min and air dried. The secondary antibody was
added to the slides and incubated for 1 hour. After washing the slides three times in PBS and air
drying, the ABC reagent was added for 30 min before washing the slides three times with PBS. DAB
solution (Vector Laboratories, Burlingame, CA, USA) was added to the slides and incubated for 5 min.
Slides were washed and stained in hematoxylin for 5 min and washed two times for 2 min. Slides were
air-dried before mounting.
4.7. Hepatic Western Blots
Protein levels were analyzed through Western blot analyses as described previously [45].
Briefly, snap-frozen livers were homogenized and diluted. Protein content of homogenates was
determined with the DC assay kit (Bio-Rad, Munich, Germany). Samples (30 µg of protein/lane)
were subjected to SDS-PAGE (10% gels), and proteins were blotted on nitrocellulose membranes.
Glyceraldehyde-3-phosphate dehydrogenase served as an endogenous control (sc166545HRP, Santa
Cruz Biotechnology, Santa Cruz, CA). The membranes were blocked and incubated with primary
antibodies for either fatty acid synthase (ab82419, Abcam, Berlin, Germany), or sterol regulatory
element-binding protein 1c (ab28481, Abcam, Berlin, Germany). Finally, membranes were
incubated with the corresponding secondary antibody, and blots were developed using enhanced
chemiluminescence. Protein quantification was performed by Multi Gauge V3.0 software (Fujifilm,
Tokyo, Japan).
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4.8. Hepatic Triglyceride Content
The hepatic triglyceride concentration was analyzed in snap-frozen liver samples using the
colorimetric assay kit (ab65336, Abcam, Berlin, Germany) according to manufacturer’s instruction
and protocol.
4.9. Quantitative Real-Time PCR
Liver homogenates were prepared using previously described methods [13,44]. RNA isolation,
reverse transcription, and detection of amplicons by real-time polymerase chain reaction were performed
as described previously [13,44]. Briefly, RNA was isolated from samples using the Qiazol reagent
(Qiagen, Hilden, Germany) as instructed by the manufacturer. The following predesigned TaqMan gene
expression assays (Applied Biosystems, Foster City, CA, USA) were used: Col1a1 (Rn00801649_g1),
Tgfb1 (Rn00572010_m1), Ccl2 (Rn00580555_m1), Emr1 (Rn01527631_m1), Il1b (Rn00580432_m1),
and Tnfa (Rn01525859_g1). Samples were normalized to the content of 18S rRNA.
4.10. Statistical Analysis
Graphs are presented as means ± standard error of mean (SEM) with a group size of n = 5 per
group. p-values < 0.05 were considered statistically significant. For gene expression experiments,
fold-change was calculated by 2-∆∆CT method and normalized to the respective control group [46].
Visualization of results and statistical analysis were performed using GraphPad Prism version 5.00 for
Windows (GraphPad Software, La Jolla, CA, USA). The Mann–Whitney U test was used to test for
statistical significant differences between groups.
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EMR1 EGF module-containing mucin-like receptor
FAS Fatty acid synthase
IL1β Interleukin 1-β
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NAFLD Non-alcoholic fatty liver disease
RAS Renin-angiotensin system
α-SMA α-smooth muscle actin
SREBP-1c Sterol regulatory element binding protein-1c
TGF-β Transforming growth factor-β
TNFα Tumor necrosis factor α
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